Refine
Year of publication
Document Type
- Article (39)
- Book (1)
- Doctoral Thesis (1)
Has Fulltext
- yes (41)
Is part of the Bibliography
- no (41)
Keywords
- LHC (6)
- ALICE (3)
- ALICE experiment (2)
- pp collisions (2)
- 900 GeV (1)
- AIWG-Expertise (1)
- Aeroplysinin-1 (1)
- Alevitische Gemeinde (1)
- Artificial Intelligence (1)
- Ausbreitungsgeschichte (1)
Institute
- Physik (21)
- Frankfurt Institute for Advanced Studies (FIAS) (20)
- Informatik (19)
- Medizin (13)
- Biowissenschaften (1)
- Georg-Speyer-Haus (1)
- Pharmazie (1)
- Senckenbergische Naturforschende Gesellschaft (1)
- Sprach- und Kulturwissenschaften (1)
Background and Aims: The prevalence of hepatitis C virus (HCV) antibodies in Germany has been estimated to be in the range of 0.4–0.63%. Screening for HCV is recommended in patients with elevated ALT levels or significant risk factors for HCV transmission only. However, 15–30% of patients report no risk factors and ALT levels can be normal in up to 20–30% of patients with chronic HCV infection. The aim of this study was to assess the HCV seroprevalence in patients visiting two tertiary care emergency departments in Berlin and Frankfurt, respectively.
Methods: Between May 2008 and March 2010, a total of 28,809 consecutive patients were screened for the presence of anti-HCV antibodies. Anti-HCV positive sera were subsequently tested for HCV-RNA.
Results: The overall HCV seroprevalence was 2.6% (95% CI: 2.4–2.8; 2.4% in Berlin and 3.5% in Frankfurt). HCV-RNA was detectable in 68% of anti-HCV positive cases. Thus, the prevalence of chronic HCV infection in the overall study population was 1.6% (95% CI 1.5–1.8). The most commonly reported risk factor was former/current injection drug use (IDU; 31.2%) and those with IDU as the main risk factor were significantly younger than patients without IDU (p<0.001) and the male-to-female ratio was 72% (121 vs. 46 patients; p<0.001). Finally, 18.8% of contacted HCV-RNA positive patients had not been diagnosed previously.
Conclusions: The HCV seroprevalence was more than four times higher compared to current estimates and almost one fifth of contacted HCV-RNA positive patients had not been diagnosed previously.